Man Group’s Matinas BioPharma MTNB Stock Holding History

Man Group’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-623	Closed	-$42K	–	1947
2020 Q4	$42K	Buy	+623	New	+$28.9K	﹤0.01%	1796

Other funds holding MTNB

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Man Group's MTNB Position: Q1 2021 in Review

Man Group sold out of Matinas BioPharma (MTNB) in Q1 2021, closing a stake of 623 shares — an estimated $42K sold.

Man Group first reported a position in MTNB in Q4 2020 and held it in 1 quarter. The position peaked at $42K in Q4 2020. 80 funds tracked by Wall St. Rank hold MTNB as of Q1 2021.

Man Group reported no remaining Matinas BioPharma position as of Q1 2021 after selling out during the quarter.
Man Group sold 623 Matinas BioPharma shares in Q1 2021, an estimated $42K.
Man Group first reported a position in Matinas BioPharma in Q4 2020 and held it in 1 quarter.
Man Group's Matinas BioPharma position peaked at $42K in Q4 2020.
80 funds tracked by Wall St. Rank held Matinas BioPharma as of Q1 2021.

Based on Man Group's 13F filing for Q1 2021, filed 17 May 2021.